12th Mar 2025 13:45
Haleon plc: Director/PDMR Shareholding
12 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Adrian Morris | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| General Counsel - PDMR | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Haleon plc | |||
b)
| LEI
| 549300PSB3WWEODCUP19 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | GB00BMX86B70
| ||||
b)
| Nature of the transaction
| Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£4.005 | 31 | ||||
£Nil | 31 (Matching Shares) | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 62 | ||||
- Price | |||||
e)
| Date of the transaction
| 11 March 2025 | |||
f)
| Place of the transaction
| London Stock Exchange (XLON) | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Tamara Rogers | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Marketing Officer - PDMR | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Haleon plc | |||
b)
| LEI
| 549300PSB3WWEODCUP19 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | GB00BMX86B70
| ||||
b)
| Nature of the transaction
| Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£4.005 | 31 | ||||
£Nil | 31 (Matching Shares) | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 62 | ||||
- Price | |||||
e)
| Date of the transaction
| 11 March 2025 | |||
f)
| Place of the transaction
| London Stock Exchange (XLON) | |||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Related Shares:
Haleon